HSP90 inhibits apoptosis and promotes growth by regulating HIF-1α abundance in hepatocellular carcinoma Corrigendum in /10.3892/ijmm.2022.5193

Liu,Xin; Chen,Shuda; Tu,Jianfeng; Cai,Wenwei; Xu,Qiuran

doi:10.3892/ijmm.2016.2482

HSP90 inhibits apoptosis and promotes growth by regulating HIF-1α abundance in hepatocellular carcinoma

Corrigendum in: /10.3892/ijmm.2022.5193

Authors:
- Xin Liu
- Shuda Chen
- Jianfeng Tu
- Wenwei Cai
- Qiuran Xu
View Affiliations

Affiliations: Department of Neurosurgery, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang 310014, P.R. China, Department of Emergency, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang 310014, P.R. China
Published online on: February 5, 2016 https://doi.org/10.3892/ijmm.2016.2482
Pages: 825-835

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Heat shock protein (HSP)90 functions as a general oncogene by targeting several well-known oncoproteins for ubiquination and proteasomal degradation. However, the clinical significance of HSP90, as well as the mechanisms responsible for the tumor-promoting effects of HSP90 in hepatocellular carcinoma (HCC) remain unclear. In this study, HSP90 and hypoxia-inducible factor (HIF)-1α expression in 60 samples of HCC tissues and matched normal tumor-adjacent tissue were assessed using immunohistochemistry (IHC) or western blot analysis. Flow cytometry, BrdU cell proliferation assay, caspase-3/7 activity assay and MTT assay were used to detect the apoptosis and proliferation of the HCC cells. The regulatory effect of HSP90 on HIF-1α in the HCC cells was confirmed by immunofluorescence staining, western blot analysis and RT-qPCR. The interaction between HIF-1α and HSP90 was analyzed by co-immunoprecipitation. A subcutaneous tumor xenograft model in nude mice was established and TUNEL assay was performed to evaluate cancer cell apoptosis and growth in vivo. We found that HSP90 expression was higher in the HCC tissues than in the normal tissues and that a high HSP90 expression correlated with poor clinicopathological characteristics, including venous infiltration, an advanced TNM stage and high pathological grading. Furthermore, we confirmed that patients with a negative expression of HSP90 had an improved 3-year survival, and that HSP90 was an independent factor for predicting the prognosis of patients with HCC. We demonstrated that HSP90 promoted HCC by inhibiting apoptosis and promoting cancer cell growth. Pearson's correlation coefficient analysis indicated that HSP90 expression positively correlated with HIF-1α protein expression in the HCC tissues. Furthermore, we found that HSP90 regulated HIF-1α protein abundance by inhibiting the ubiquitination and proteasomal degradation of HIF-1α in HCC cells. Additionally, the upregulation of HIF-1α expression partially abrogated HSP90 siRNA-induced HCC cell growth arrest and apoptosis in vitro and in vivo. These results indicate that HSP90 may be used as a prognostic marker and that HIF-1α may be one of the potential therapeutic targets of HSP90 in HCC.

View Figures

View References

1	Buonaguro L, Petrizzo A, Tagliamonte M, Tornesello ML and Buonaguro FM: Challenges in cancer vaccine development for hepatocellular carcinoma. J Hepatol. 59:897–903. 2013. View Article : Google Scholar : PubMed/NCBI
2	Xu Q, Liu X, Zheng X, Yao Y, Wang M and Liu Q: The transcriptional activity of Gli1 is negatively regulated by AMPK through Hedgehog partial agonism in hepatocellular carcinoma. Int J Mol Med. 34:733–741. 2014.PubMed/NCBI
3	Kiang JG and Tsokos GC: Heat shock protein 70 kDa: molecular biology, biochemistry, and physiology. Pharmacol Ther. 80:183–201. 1998. View Article : Google Scholar : PubMed/NCBI
4	Welch WJ: Mammalian stress response: cell physiology, structure/function of stress proteins, and implications for medicine and disease. Physiol Rev. 72:1063–1081. 1992.PubMed/NCBI
5	Milicevic Z, Bogojevic D, Mihailovic M, Petrovic M and Krivokapic Z: Molecular characterization of hsp90 isoforms in colorectal cancer cells and its association with tumour progression. Int J Oncol. 32:1169–1178. 2008.PubMed/NCBI
6	Nimmanapalli R, O'Bryan E and Bhalla K: Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res. 61:1799–1804. 2001.PubMed/NCBI
7	Pascale RM, Simile MM, Calvisi DF, Frau M, Muroni MR, Seddaiu MA, Daino L, Muntoni MD, De Miglio MR, Thorgeirsson SS and Feo F: Role of HSP90, CDC37, and CRM1 as modulators of P16(INK4A) activity in rat liver carcinogenesis and human liver cancer. Hepatology. 42:1310–1319. 2005. View Article : Google Scholar : PubMed/NCBI
8	Yano M, Naito Z, Tanaka S and Asano G: Expression and roles of heat shock proteins in human breast cancer. Jpn J Cancer Res. 87:908–915. 1996. View Article : Google Scholar : PubMed/NCBI
9	Xu QR, Liu X, Yao YM and Liu QG: Expression of HSP90 and HIF-1α in human colorectal cancer tissue and its significance. Asian Pac J Trop Med. 7:720–724. 2014. View Article : Google Scholar
10	Palsson-McDermott EM, Curtis AM, Goel G, Lauterbach MA, Sheedy FJ, Gleeson LE, van den Bosch MW, Quinn SR, Domingo-Fernandez R, Johnston DG, et al: Pyruvate kinase M2 regulates Hif-1α activity and IL-1β induction and is a critical determinant of the Warburg effect in LPS-activated macrophages. Cell Metabolism. 21:65–80. 2015. View Article : Google Scholar
11	Wang GL, Jiang B-H, Rue EA and Semenza GL: Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O₂ tension. Proc Natl Acad Sci USA. 92:5510–5514. 1995. View Article : Google Scholar
12	Krishnamachary B, Berg-Dixon S, Kelly B, Agani F, Feldser D, Ferreira G, Iyer N, LaRusch J, Pak B, Taghavi P and Semenza GL: Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res. 63:1138–1143. 2003.PubMed/NCBI
13	Mizukami Y, Li J, Zhang X, Zimmer MA, Iliopoulos O and Chung DC: Hypoxia-inducible factor-1-independent regulation of vascular endothelial growth factor by hypoxia in colon cancer. Cancer Res. 64:1765–1772. 2004. View Article : Google Scholar : PubMed/NCBI
14	Cao D, Hou M, Guan YS, Jiang M, Yang Y and Gou HF: Expression of HIF-1alpha and VEGF in colorectal cancer: association with clinical outcomes and prognostic implications. BMC Cancer. 9:4322009. View Article : Google Scholar : PubMed/NCBI
15	Tu K, Yang W, Li C, Zheng X, Lu Z, Guo C, Yao Y and Liu Q: Fbxw7 is an independent prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma. Mol Cancer. 13:110. 2014. View Article : Google Scholar : PubMed/NCBI
16	Riis ML, Lüders T, Nesbakken AJ, Vollan HS, Kristensen V and Bukholm IR: Expression of BMI-1 and Mel-18 in breast tissue-a diagnostic marker in patients with breast cancer. BMC Cancer. 10:6862010. View Article : Google Scholar
17	Tu K, Zheng X, Zan X, Han S, Yao Y and Liu Q: Evaluation of Fbxw7 expression and its correlation with the expression of c-Myc, cyclin E and p53 in human hepatocellular carcinoma. Hepatol Res. 42:904–910. 2012. View Article : Google Scholar : PubMed/NCBI
18	Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT, Zender L, Lowe SW, Poon RT and Luk JM: Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer. 115:4576–4585. 2009. View Article : Google Scholar : PubMed/NCBI
19	Xu Q, Liu X, Zheng X, Yao Y and Liu Q: PKM2 regulates Gli1 expression in hepatocellular carcinoma. Oncol Lett. 8:1973–1979. 2014.PubMed/NCBI
20	Tu K, Zheng X, Zhou Z, Li C, Zhang J, Gao J, Yao Y and Liu Q: Recombinant human adenovirus-p53 injection induced apoptosis in hepatocellular carcinoma cell lines mediated by p53-Fbxw7 pathway, which controls c-Myc and cyclin E. PLoS One. 8:e685742013. View Article : Google Scholar : PubMed/NCBI
21	Zheng X, Vittar NB, Gai X, Fernandez-Barrena MG, Moser CD, Hu C, Almada LL, McCleary-Wheeler AL, Elsawa SF, Vrabel AM and Shire AM: The transcription factor GLI1 mediates TGFβ1 driven EMT in hepatocellular carcinoma via a SNAI1-dependent mechanism. PLoS One. 7:e495812012. View Article : Google Scholar
22	Cao S, Yang S, Wu C, Wang Y, Jiang J and Lu Z: Protein expression of hypoxia-inducible factor-1 alpha and hepatocellular carcinoma: a systematic review with meta-analysis. Clin Res Hepatol Gastroenterol. 38:598–603. 2014. View Article : Google Scholar : PubMed/NCBI
23	Xue N, Jin J, Liu D, Yan R, Zhang S, Yu X and Chen X: Antiproliferative effect of HSP90 inhibitor Y306zh against pancreatic cancer is mediated by interruption of AKT and MAPK signaling pathways. Curr Cancer Drug Targets. 14:671–683. 2014. View Article : Google Scholar : PubMed/NCBI
24	Haarberg HE, Paraiso KH, Wood E, Rebecca VW, Sondak VK, Koomen JM and Smalley KS: Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma. Mol Cancer Ther. 12:901–912. 2013. View Article : Google Scholar : PubMed/NCBI
25	Lu XG, Xing CG, Feng YZ, Chen J and Deng C: Clinical significance of immunohistochemical expression of hypoxia-inducible factor-1alpha as a prognostic marker in rectal adenocarcinoma. Clin Colorectal Cancer. 5:350–353. 2006. View Article : Google Scholar : PubMed/NCBI
26	Liu YV and Semenza GL: RACK1 vs. HSP90: competition for HIF-1 alpha degradation vs. stabilization. Cell Cycle. 6:656–659. 2007. View Article : Google Scholar : PubMed/NCBI
27	Bagatell R and Whitesell L: Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol Cancer Ther. 3:1021–1030. 2004.PubMed/NCBI
28	Goetz MP, Toft DO, Ames MM and Erlichman C: The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol. 14:1169–1176. 2003. View Article : Google Scholar : PubMed/NCBI
29	Whitesell L and Lindquist SL: HSP90 and the chaperoning of cancer. Nat Rev Cancer. 5:761–772. 2005. View Article : Google Scholar : PubMed/NCBI
30	Workman P, Burrows F, Neckers L and Rosen N: Drugging the cancer chaperone HSP90: Combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann NY Acad Sci. 1113:202–216. 2007. View Article : Google Scholar : PubMed/NCBI
31	Qi XL, Bo AH, Yue SC, Wang CY and Liu HB: Heat shock protein 90 mrna expressed in adenocarcinoma and adenoma of significance. Proceed Military Academy Medical Sci. 30:351–353. 2011.
32	Bo AH, Dai J, Li SG, Zuo DS, Chen XL, Yan YJ, et al: HSP90 mRNA expressed in stomach and large intestine cancer research. Chin J Histochem Cytochem. 14:213–216. 2011.
33	Pick E, Kluger Y, Giltnane JM, Moeder C, Camp RL, Rimm DL and Kluger HM: High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res. 67:2932–2937. 2007. View Article : Google Scholar : PubMed/NCBI
34	Kang GH, Lee EJ, Jang KT, Kim KM, Park CK, Lee CS, Kang DY, Lee SH, Sohn TS and Kim S: Expression of HSP90 in gastrointestinal stromal tumours and mesenchymal tumours. Histopathology. 56:694–701. 2010. View Article : Google Scholar : PubMed/NCBI
35	Zhao S, Li H, Jiang C, Ma T, Wu C, Huo Q and Liu H: 17-Demethoxy-reblastatin, an Hsp90 inhibitor, induces mitochondria-mediated apoptosis through downregulation of Mcl-1 in human hepatocel-lular carcinoma cells. J Bioenerg Biomembr. 47:373–381. 2015. View Article : Google Scholar : PubMed/NCBI